Safety of intravenous insulin aspart compared to regular human insulin in patients undergoing ICU monitoring post cardiac surgery: an Indian experience

Journal of Diabetes & Metabolic Disorders

Anil Bhoraskar²  Shwetal Shinde²  Harshvi Shah²  Harshad Malve¹  Manoj Chawla² 

[1] Lead Medical for Asia Pacific region, Ferring Pharmaceuticals, 24th Floor, Sunshine Towers, Senapati Bapat Marg, Elphinstone (West), Mumbai 400013, India;Department of Diabetology, Asian Heart Institute, G/N Block, Bandra Kurla Complex, Bandra East, Mumbai 400051, Maharashtra, India

关键词: Intensive care;    Hyperglycemia;    Diabetes;    Cardiac surgery;    CABG;   

Others  :  1164683
DOI  :  10.1186/s40200-015-0152-3

 received in 2014-04-08, accepted in 2015-03-19,  发布年份 2015

【 摘 要 】

Background

Poor perioperative glycemic control increases risk of infection, cardiovascular accidents and mortality in patients undergoing surgery. Tight glycemic control by insulin therapy is known to yield better outcomes in such patients. Intravenous (IV) insulin therapy with or without adjunctive subcutaneous insulin therapy is the mainstay of managing hyperglycemia in perioperative period. This observational study assessed the safety of IV Insulin Aspart (IAsp) as compared to Regular Human Insulin (RHI) in patients undergone cardiac surgery at a tertiary care hospital.

Methods

203 patients received IV IAsp (n = 103) and RHI (n = 100) respectively. Safety was assessed by frequency and severity of adverse events (AEs) & serious adverse events (SAEs) during hospitalization.

Results

IAsp effectively controlled mean blood glucose levels to 159.87 ± 41.41 mg/dl similar to RHI (160.77 ± 44.39 mg/dl). No serious adverse event was reported. The incidence of hypoglycemia was similar in both the groups. The insulin infusion rate, time for which insulin infusion was withheld and mean blood glucose during hypoglycemia was significantly high in RHI group.

Conclusion

This study has shown similar safety of IV IAsp as compared to IV RHI in the post cardiac surgery patients. However physicians preferred IAsp as it offers advantage during transition. IV IAsp offers an effective and safe option for managing hyperglycemia in patients in ICU post cardiac procedures.

【 授权许可】

   
2015 Chawla et al.; licensee BioMed Central.

【 参考文献 】

• [1]Centers for Disease Control and Prevention. Crude and age-adjusted percentage of civilian, non-institutionalized population with diagnosed diabetes, United States, 1980–2008 [article online]. Available from www.cdc.gov/diabetes/statistics/prev/national/figage.htm. Accessed on November 2013.
• [2]Levetan CS, Passaro M, Jablonski K, Kass M, Ratner RE: Unrecognized diabetes among hospitalized patients. Diabetes Care 1998, 21:246-9.
• [3]Krinsley JS: Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003, 78:1471-8.
• [4]American Diabetes Association: Economic costs of diabetes in the U.S. in 2007 Diabetes Care 2008, 31:596-615.
• [5]International Diabetes Federation: IDF Diabetes Atlas. 6th edition. International Diabetes Federation, Brussels, Belgium; 2013.
• [6]Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al.: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345(19):1359-67.
• [7]Minakata K, Sakata R: Perioperative control of blood glucose level in cardiac surgery. Gen Thorac Cardiovasc Surg 2013, 61:61-6.
• [8]Shogbon AO, Levy SB: Intensive glucose control in the management of diabetes mellitus and inpatient hyperglycemia. Am J Health Syst Pharm 2010, 67(10):798-805.
• [9]Charpentier G, Dardari D, Riveline JP: How should postprandial glycemia be treated? Diabetes Metab 2006, 32(Spec No2):2S21-7.
• [10]Owens D, Vora J: Insulin aspart: a review. Expert Opin Drug Metab Toxicol 2006, 2(5):793-804.
• [11]Frier BM, Ewing FM, Lindholm A, Hylleberg B, Kanc K: Symptomatic and counter-regulatory hormonal responses to acute hypoglycemia induced by insulin aspart and soluble human insulin in Type 1 diabetes. Diabetes Metab Res Rev 2000, 16(4):262-8.
• [12]Bode BW, Braithwaite SS, Steed RD, Davidson PC: Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapy. Endocr Pract 2004, 10(Suppl 2):71-80.
• [13]DeSantis AJ, Schmeltz LR, Schmidt K, O’Shea-Mahler E, Rhee C, Wells A, et al.: Inpatient management of hyperglycemia: the Northwestern experience. Endocr Pract 2006, 12(5):491-505.
• [14]Krinsley J, Grissler B: Intensive glycemic management in critically ill patients. Jt Comm J Qual Patient Saf 2005, 31(6):308-12.
• [15]Rady MY, Johnson DJ, Patel BM, Larson JS, Helmers RA: Influence of individual characteristics on outcome of glycemic control in intensive care unit patients with or without diabetes mellitus. Mayo Clin Proc 2005, 80(12):1558-67.
• [16]Chapman TM, Noble S, Goa KL, et al.: Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2002, 62(13):1945-81.
• [17]Robinson RT, Noble S, Goa KL: Comparative effect of human soluble insulin and insulin aspart upon hypoglycemia-induced alterations in cardiac repolarization. Br J Clin Pharmacol 2003, 55(3):246-51.
• [18]Schmeltz LR, DeSantis AJ, Schmidt K, O’Shea-Mahler E, Rhee C, Brandt S, et al.: Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia. Endocr Pract 2006, 12:641-50.
• [19]Udwadia F, Bhattacharyya A, Seshiah V, Sethi BK, Kumar S, Subbanna P, et al.: Intravenous insulin aspart in a hospital setting: results from an observational study examining patient outcomes and physician preferences. Diabetes Manage 2012, 2(2):103-10.
• [20]American Diabetes Association: Standards of medical care in diabetes - 2013 Diabetes Care 2013, 36(Sup.1):S1-66.
• [21]Brunner GA, Hirschberger S, Sendlhofer G, Wutte A, Ellmerer M, Balent B, et al.: Postprandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus. Diabet Med 2000, 17:371-5.
• [22]Jovanovic L, Giammattei J, Acquistapace M, Bornstein K, Sommermann E, Pettitt DJ: Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size. Clin Ther 2004, 26:1492-7.
• [23]Madsen H, Frankel EH. The Hitchhiker’s guide to parenteral nutrition management for adult patients. Pract Gastroenterology, series #40. 2006:46–68.
• [24]Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al.: American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract 2009, 15:353-69.
• [25]Bernard JB, Munoz C, Harper J, Muriello M, Rico E, Baldwin D: Treatment of inpatient hyperglycemia beginning in the emergency department: a randomized trial using insulins aspart and detemir compared with usual care. J Hosp Med 2011, 6:279-84.
• [26]Dungan K, Hall C, Schuste D, Osei K: Differential response between diabetes and stress-induced hyperglycemia to algorithmic use of detemir and flexible mealtime aspart among stable postcardiac surgery patients requiring intravenous insulin. Diabetes Obes Metab 2011, 13:1130-5.